Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Image Source: Zacks Investment Research Lilly’s tremendous success with Mounjaro and Zepbound made it the biggest drugmaker in the world, with a market cap of around $800 million. However ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase ... freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on ...

"Short of guaranteeing success, which they can't do because they ... to plan ahead for this year. Lilly's Zepbound and Novo's Wegovy dominate a market for weight-loss treatments that analysts ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a big revenue ... is essential to our mission of empowering investor success. We provide a platform for our authors to ...

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...